Literature DB >> 23121978

Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors.

Hyo Jin Park1, Anthony Kusnadi, Eun-Jung Lee, Won Woo Kim, Byoung Chul Cho, Ik Jae Lee, Jinsil Seong, Sang-Jun Ha.   

Abstract

Foxp3(+) regulatory T (T(reg)) cells are dominant suppressor cells which regulate conventional T (T(conv)) cells. Inside tumor microenvironment, T(reg) cells have been known to become potent in suppressing T(conv) cell responses, thereby enabling tumor cells to circumvent immune response. However, the underlying mechanism by which tumor-infiltrating T(reg) cells display enhanced suppressive function is still unresolved. To understand characteristics and function of tumor-infiltrating T(reg) cells as well as T(conv) cells in the tumor site, we analyzed their phenotypes either within tumor burden or at distant site of tumor using both heterotopic and orthotopic mouse cancer models. Compared to CD8(+) T cells at distant site of tumor, tumor-infiltrating CD8(+) T cells dramatically upregulated programmed death 1 (PD-1) and other inhibitory receptors, thereby being more exhausted functionally. Tumor-infiltrating CD4(+) T cells also expressed higher level of PD-1 than CD4(+) T cells at distant site of tumor but very surprisingly, upregulation of PD-1 occurred in CD4(+)Foxp3(+) T(reg) as well as CD4(+)Foxp3(-) T(conv) cells. Moreover, tumor infiltrating T(reg) cells upregulated other inhibitory receptors such as T cell immunoglobulin mucin 3 (TIM-3), cytotoxic T lymphocyte antigen-4 (CTLA-4), glucocorticoid-induced tumor necrosis factor receptor (GITR), and lymphocyte activation gene-3 (LAG-3). These results suggest that upregulation of PD-1 and other inhibitory receptors on tumor-infiltrating T(reg) cells is related with their enhanced suppressive function.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23121978     DOI: 10.1016/j.cellimm.2012.07.001

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  38 in total

1.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

Review 2.  Regulatory T cells in nonlymphoid tissues.

Authors:  Dalia Burzyn; Christophe Benoist; Diane Mathis
Journal:  Nat Immunol       Date:  2013-09-18       Impact factor: 25.606

3.  Expression of programmed death-1 ligand (PD-L1) in tumor-infiltrating lymphocytes is associated with favorable spinal chordoma prognosis.

Authors:  Ming-Xiang Zou; An-Bo Peng; Guo-Hua Lv; Xiao-Bin Wang; Jing Li; Xiao-Ling She; Yi Jiang
Journal:  Am J Transl Res       Date:  2016-07-15       Impact factor: 4.060

4.  Tumor-infiltrating PD1-Positive Lymphocytes and FoxP3-Positive Regulatory T Cells Predict Distant Metastatic Relapse and Survival of Clear Cell Renal Cell Carcinoma.

Authors:  Myoung Jae Kang; Kyoung Min Kim; Jun Sang Bae; Ho Sung Park; Ho Lee; Myoung Ja Chung; Woo Sung Moon; Dong Geun Lee; Kyu Yun Jang
Journal:  Transl Oncol       Date:  2013-06-01       Impact factor: 4.243

5.  Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors.

Authors:  Edmund K Moon; Liang-Chuan Wang; Douglas V Dolfi; Caleph B Wilson; Raghuveer Ranganathan; Jing Sun; Veena Kapoor; John Scholler; Ellen Puré; Michael C Milone; Carl H June; James L Riley; E John Wherry; Steven M Albelda
Journal:  Clin Cancer Res       Date:  2014-06-11       Impact factor: 12.531

6.  CLINICAL SIGNIFICANCE OF PD-L1 EXPRESSION IN PARATHYROID CANCER.

Authors:  X Du; L Wang; B Shen; H He; H Chang; B Wei
Journal:  Acta Endocrinol (Buchar)       Date:  2016 Oct-Dec       Impact factor: 0.877

Review 7.  Interleukin-2 and regulatory T cells in rheumatic diseases.

Authors:  Antonios G A Kolios; George C Tsokos; David Klatzmann
Journal:  Nat Rev Rheumatol       Date:  2021-11-02       Impact factor: 20.543

Review 8.  A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy.

Authors:  Robert D Leone; Ying-Chun Lo; Jonathan D Powell
Journal:  Comput Struct Biotechnol J       Date:  2015-04-08       Impact factor: 7.271

9.  The tumor microenvironment: a pitch for multiple players.

Authors:  Giovanna Schiavoni; Lucia Gabriele; Fabrizio Mattei
Journal:  Front Oncol       Date:  2013-04-17       Impact factor: 6.244

10.  Convergences and divergences of thymus- and peripherally derived regulatory T cells in cancer.

Authors:  Alessia Burocchi; Mario P Colombo; Silvia Piconese
Journal:  Front Immunol       Date:  2013-08-27       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.